Volume 12 Issue 3
May  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2021  >  12(3): 249-256
Wang Genshu. Improving efficacy of liver transplantation for hepatocellular carcinoma by comprehensive treatment[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 249-256. doi: 10.3969/j.issn.1674-7445.2021.03.001
Citation: Wang Genshu. Improving efficacy of liver transplantation for hepatocellular carcinoma by comprehensive treatment[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 249-256. doi: 10.3969/j.issn.1674-7445.2021.03.001
shu

Improving efficacy of liver transplantation for hepatocellular carcinoma by comprehensive treatment

doi: 10.3969/j.issn.1674-7445.2021.03.001

  • Department of Hepatic Surgery, Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Wang Genshu, Email: wgsh168@163.com
  • Received Date: 2021-03-22
    Available Online: 2021-05-19
  • Publish Date: 2021-05-15
    Abstract
  • Currently, several major challenges still exist in liver transplantation for hepatocellular carcinoma (HCC), including the opportunity of liver transplantation for HCC patients beyond selection criteria, drop-out from the waiting list for HCC patients within selection criteria due to tumor progression and the tumor recurrence after liver transplantation. In recent years, revolutionary efficacy has been achieved in treating advanced HCC by employing systemic drugs, such as lenvatinib and systemic drug-based comprehensive treatment, which also sheds light on the down-staging therapy and bridging therapy for HCC patients listed for liver transplantation, and prevention and treatment of tumor recurrence after liver transplantation for HCC individuals. Systemic drug-based comprehensive treatment probably has the potential to improve the clinical efficacy of liver transplantation for HCC, which deserves in-depth investigation. In this review, we summarize the progress on down-staging therapy, bridging therapy as well as prevention and treatment of tumor recurrence after liver transplantation for HCC individuals, aiming to provide reference for clinical managementof HCC.

     

    • FullText(HTML)
  • loading
    • References(51)
  • [1]
    陈万青, 李贺, 孙可欣, 等. 2014年中国恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志, 2018, 40(1): 5-13. DOI: 10.3760/cma.j.issn.0253-3766.2018.01.002.

    CHEN WQ, LI H, SUN KX, et al. Report of cancer incidence and mortality in China, 2014[J]. Chin J Oncol, 2018, 40(1): 5-13. DOI: 10.3760/cma.j.issn.0253-3766.2018.01.002.
    [2]
    PARK JW, CHEN M, COLOMBO M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study[J]. Liver Int, 2015, 35(9): 2155-2166. DOI: 10.1111/liv.12818.
    [3]
    MAZZAFERRO V, REGALIA E, DOCI R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699. DOI: 10.1056/NEJM199603143341104.
    [4]
    MAZZAFERRO V, BHOORI S, SPOSITO C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience[J]. Liver Transpl, 2011, 17(Suppl 2): S44-S57. DOI: 10.1002/lt.22365.
    [5]
    SANTOPAOLO F, LENCI I, MILANA M, et al. Liver transplantation for hepatocellular carcinoma: where do we stand? [J]. World J Gastroenterol, 2019, 25(21): 2591-2602. DOI: 10.3748/wjg.v25.i21.2591.
    [6]
    XU DW, WAN P, XIA Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: a review[J]. World J Gastroenterol, 2016, 22(12): 3325-3334. DOI: 10.3748/wjg.v22.i12.3325.
    [7]
    龚新雷, 秦叔逵. 系统化疗治疗晚期肝细胞癌的现状和研究进展[J]. 中国新药杂志, 2014, 23(17): 2008-2017. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201417011.htm

    GONG XL, QIN SK. Current situation and research progress of systemic chemotherapy in the treatment of advanced hepatocellular carcinoma[J]. Chin J New Drugs, 2014, 23(17): 2008-2017. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201417011.htm
    [8]
    刘琳, 郑英慧, 韩力, 等. 含奥沙利铂系统化疗方案治疗晚期原发性肝癌有效性和安全性的前瞻性研究荟萃分析[J]. 临床肿瘤学杂志, 2015, 20(9): 769-779. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201509001.htm

    LIU L, ZHENG YH, HAN L, et al. Efficacy and safety of oxaliplatin-based chemotherapy for advanced primary hepatic carcinoma: a systemic review and Meta analysis of prospective studies[J]. Chin Clin Oncol, 2015, 20(9): 769-779. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201509001.htm
    [9]
    QIN S, WU Q. Systemic chemotherapy with oxaliplatin is a good option for advanced hepatocellular carcinoma[J]. Hepat Oncol, 2015, 2(3): 203-207. DOI: 10.2217/hep.15.14.
    [10]
    QIN S, GONG X. Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China[J]. Hepat Oncol, 2016, 3(1): 71-81. DOI: 10.2217/hep.15.42.
    [11]
    PARIKH ND, WALJEE AK, SINGAL AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis[J]. Liver Transpl, 2015, 21(9): 1142-1152. DOI: 10.1002/lt.24169.
    [12]
    AFFONSO BB, GALASTRI FL, DA MOTTA LEAL FILHO JM, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging[J]. World J Gastroenterol, 2019, 25(37): 5687-5701. DOI: 10.3748/wjg.v25.i37.5687.
    [13]
    PAVEL MC, FUSTER J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: future directions[J]. World J Gastroenterol, 2018, 24(32): 3626-3636. DOI: 10.3748/wjg.v24.i32.3626.
    [14]
    CHAPMAN WC, MAJELLA DOYLE MB, STUART JE, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation[J]. Ann Surg, 2008, 248(4): 617-625. DOI: 10.1097/SLA.0b013e31818a07d4.
    [15]
    YAO FY, KERLAN RK JR, HIROSE R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis[J]. Hepatology, 2008, 48(3): 819-827. DOI: 10.1002/hep.22412.
    [16]
    RAVAIOLI M, GRAZI GL, PISCAGLIA F, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria[J]. Am J Transplant, 2008, 8(12): 2547-2557. DOI: 10.1111/j.1600-6143.2008.02409.x.
    [17]
    中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.

    Branch of Organ Transplantation of Chinese Medical Doctor Association, Branch of Organ Transplantation of Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma(2018 edition) [J]. J Clin Hepatol, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.
    [18]
    KIM MN, KIM BK, HAN KH, et al. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(3): 335-348. DOI: 10.1586/17474124.2015.959929.
    [19]
    European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943. DOI: 10.1016/j.jhep.2011.12.001.
    [20]
    ROBERTS JP, VENOOK A, KERLAN R, et al. Hepatocellular carcinoma: ablate and wait versus rapid transplantation[J]. Liver Transpl, 2010, 16(8): 925-929. DOI: 10.1002/lt.22103.
    [21]
    MILLONIG G, GRAZIADEI IW, FREUND MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma[J]. Liver Transpl, 2007, 13(2): 272-279. DOI: 10.1002/lt.21033.
    [22]
    VICTOR DW 3RD, MONSOUR HP JR, BOKTOUR M, et al. Outcomes of liver transplantation for hepatocellular carcinoma beyond the University of California San Francisco criteria: a single-center experience[J]. Transplantation, 2020, 104(1): 113-121. DOI: 10.1097/TP.0000000000002835.
    [23]
    CLAVIEN PA, LESURTEL M, BOSSUYT PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncol, 2012, 13(1): e11-e22. DOI: 10.1016/S1470-2045(11)70175-9.
    [24]
    VOLK ML, VIJAN S, MARRERO JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria[J]. Am J Transplant, 2008, 8(4): 839-846. DOI: 10.1111/j.1600-6143.2007.02138.x.
    [25]
    SHARR WW, CHAN SC, LO CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation[J]. Transplantation, 2014, 97 (Suppl 8): S10-S17. DOI: 10.1097/01.tp.0000446267.19148.21.
    [26]
    HE M, LI Q, ZOU R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250.
    [27]
    ZHU XD, TANG ZY, SUN HC. Targeting angiogenesis for liver cancer: past, present, and future[J]. Genes Dis, 2020, 7(3): 328-335. DOI: 10.1016/j.gendis.2020.03.010.
    [28]
    EILARD MS, ANDERSSON M, NAREDI P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation[J]. BMC Cancer, 2019, 19(1): 568. DOI: 10.1186/s12885-019-5760-8.
    [29]
    LIU Z, FU Z, LI G, et al. Downstaging of recurrent advanced hepatocellular carcinoma after lenvatinib treatment: opportunities or pitfalls? a case report[J]. Onco Targets Ther, 2020, 13: 10267-10273. DOI: 10.2147/OTT.S261521.
    [30]
    DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6): 1054-1062. DOI: 10.21037/jgo.2018.07.05.
    [31]
    NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient? [J]. Am J Transplant, 2020, 20(3): 879-883. DOI: 10.1111/ajt.15617.
    [32]
    SCHWACHA-EIPPER B, MINCIUNA I, BANZ V, et al. Immunotherapy as a downstaging therapy for liver transplantation[J]. Hepatology, 2020, 72(4): 1488-1490. DOI: 10.1002/hep.31234.
    [33]
    TABRIZIAN P, FLORMAN SS, SCHWARTZ ME. PD-1 inhibitor as bridge therapy to liver transplantation? [J]. Am J Transplant, 2020, 21(5): 1979-1980. DOI: 10.1111/ajt.16448.
    [34]
    LLOVET JM, MAS X, APONTE JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation[J]. Gut, 2002, 50(1): 123-128. DOI: 10.1136/gut.50.1.123.
    [35]
    MAJNO P, LENCIONI R, MORNEX F, et al. Is the treatment of hepatocellular carcinoma on the waiting list necessary? [J]. Liver Transpl, 2011, 17 (Suppl 2): S98-S108. DOI: 10.1002/lt.22391.
    [36]
    CESCON M, CUCCHETTI A, RAVAIOLI M, et al. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. impact on transplantability and recurrence rate[J]. J Hepatol, 2013, 58(3): 609-618. DOI: 10.1016/j.jhep.2012.09.021.
    [37]
    DÍAZ-SÁNCHEZ A, MATILLA A, NÚÑEZ O, et al. Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival[J]. Gastroenterol Hepatol, 2010, 33(3): 155-164. DOI: 10.1016/j.gastrohep.2009.10.001.
    [38]
    BHOORI S, SPOSITO C, GERMINI A, et al. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis[J]. Transpl Int, 2010, 23(7): 712-722. DOI: 10.1111/j.1432-2277.2010.01111.x.
    [39]
    AU KP, CHOK KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: a proposed management algorithm[J]. World J Gastroenterol, 2018, 24(45): 5081-5094. DOI: 10.3748/wjg.v24.i45.5081.
    [40]
    刘召波, 栗光明. 肝移植术后肝癌复发防治进展[J]. 临床肝胆病杂志, 2021, 37(2): 267-271. DOI: 10.3969/j.issn.1001-5256.2021.02.006.

    LIU SB, LI GM. Advances in the prevention and treatment of hepatocellular carcinoma recurrence after liver transplantation[J]. J Clin Hepatol, 2021, 37(2): 267-271. DOI: 10.3969/j.issn.1001-5256.2021.02.006.
    [41]
    李海波, 汪国营, 蔡建业, 等. 2020年ATC肝移植研究前沿盘点[J]. 器官移植, 2021, 12(1): 29-36. DOI: 10.3969/j.issn.1674-7445.2021.01.005.

    LI HB, WANG GY, CAI JY, et al. Summary of the research frontiers of liver transplantation in 2020 ATC[J]. Organ Transplant, 2021, 12(1): 29-36. DOI: 10.3969/j.issn.1674-7445.2021.01.005.
    [42]
    SCHMITZ S, LURJE G, ULMER F, et al. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(3): 228-236. DOI: 10.1016/j.hbpd.2019.01.004.
    [43]
    HABIBOLLAHI P, HUNT S, GADE T, et al. The impact of bridging LRT on survival in patients listed for liver transplantation[J]. Cardiovasc Intervent Radiol, 2018, 41(1): 112-119. DOI: 10.1007/s00270-017-1759-1.
    [44]
    中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1): 8-14, 28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.

    Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. Organ Transplant, 2021, 12(1): 8-14, 28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.
    [45]
    SARICI B, ISIK B, YILMAZ S. Management of recurrent HCC after liver transplantation[J]. J Gastrointest Cancer, 2020, 51(4): 1197-1199. DOI: 10.1007/s12029-020-00498-6.
    [46]
    FISHER J, ZEITOUNI N, FAN W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review[J]. J Am Acad Dermatol, 2020, 82(6): 1490-1500. DOI: 10.1016/j.jaad.2019.07.005.
    [47]
    ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1): 106. DOI: 10.1186/s40425-019-0585-1.
    [48]
    DE BRUYN P, VAN GESTEL D, OST P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? [J]. Curr Opin Oncol, 2019, 31(2): 54-64. DOI: 10.1097/CCO.0000000000000505.
    [49]
    MUNKER S, DE TONI EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7): 970-973. DOI: 10.1177/2050640618774631.
    [50]
    RAMMOHAN A, REDDY MS, FAROUK M, et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet? [J]. Hepatology, 2018, 67(3): 1166-1168. DOI: 10.1002/hep.29575.
    [51]
    WANG YC, WU TJ, WU TH, et al. The risk factors to predict acute rejection in liver transplantation[J]. Transplant Proc, 2012, 44(2): 526-528. DOI: 10.1016/j.transproceed.2012.01.041.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (753) PDF downloads(85) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return